• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨质疏松症和纤维肌痛的常见 miRNA:综述。

Common miRNAs of Osteoporosis and Fibromyalgia: A Review.

机构信息

Platform of Clinical Investigation Department, Inserm CIC 1405, University Hospital Clermont-Ferrand, F-63000 Clermont-Ferrand, France.

Inserm 1107, Neuro-Dol, University Clermont Auvergne, F-63000 Clermont-Ferrand, France.

出版信息

Int J Mol Sci. 2023 Aug 31;24(17):13513. doi: 10.3390/ijms241713513.

DOI:10.3390/ijms241713513
PMID:37686318
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10488272/
Abstract

A significant clinical association between osteoporosis (OP) and fibromyalgia (FM) has been shown in the literature. Given the need for specific biomarkers to improve OP and FM management, common miRNAs might provide promising tracks for future prevention and treatment. The aim of this review is to identify miRNAs described in OP and FM, and dysregulated in the same direction in both pathologies. The PubMed database was searched until June 2023, with a clear mention of OP, FM, and miRNA expression. Clinical trials, case-control, and cross-sectional studies were included. Gray literature was not searched. Out of the 184 miRNAs found in our research, 23 are shared by OP and FM: 7 common miRNAs are dysregulated in the same direction for both pathologies (3 up-, 4 downregulated). The majority of these common miRNAs are involved in the Wnt pathway and the cholinergic system and a possible link has been highlighted. Further studies are needed to explore this relationship. Moreover, the harmonization of technical methods is necessary to confirm miRNAs shared between OP and FM.

摘要

骨质疏松症 (OP) 和纤维肌痛 (FM) 之间存在显著的临床关联,这在文献中已有显示。鉴于需要特定的生物标志物来改善 OP 和 FM 的管理,常见的 miRNAs 可能为未来的预防和治疗提供有希望的途径。本综述的目的是确定在 OP 和 FM 中描述的 miRNAs,并确定在两种病理中以相同方向失调的 miRNAs。检索了 PubMed 数据库,截至 2023 年 6 月,明确提到了 OP、FM 和 miRNA 表达。纳入了临床试验、病例对照和横断面研究。未检索灰色文献。在我们的研究中发现的 184 个 miRNAs 中,有 23 个在 OP 和 FM 中共有:有 7 个常见的 miRNAs 在两种病理中以相同方向失调(3 个上调,4 个下调)。这些常见的 miRNAs 大多与 Wnt 途径和胆碱能系统有关,并强调了它们之间可能存在联系。需要进一步的研究来探索这种关系。此外,有必要协调技术方法以确认 OP 和 FM 之间共享的 miRNAs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/9d054cf9cc12/ijms-24-13513-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/3eac5f0ad960/ijms-24-13513-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/6754bc6c5d52/ijms-24-13513-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/83f83b761a82/ijms-24-13513-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/9d054cf9cc12/ijms-24-13513-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/3eac5f0ad960/ijms-24-13513-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/6754bc6c5d52/ijms-24-13513-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/83f83b761a82/ijms-24-13513-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89bd/10488272/9d054cf9cc12/ijms-24-13513-g004.jpg

相似文献

1
Common miRNAs of Osteoporosis and Fibromyalgia: A Review.骨质疏松症和纤维肌痛的常见 miRNA:综述。
Int J Mol Sci. 2023 Aug 31;24(17):13513. doi: 10.3390/ijms241713513.
2
Identification of a microRNA signature for the diagnosis of fibromyalgia.用于诊断纤维肌痛的微小RNA特征的鉴定。
PLoS One. 2015 Mar 24;10(3):e0121903. doi: 10.1371/journal.pone.0121903. eCollection 2015.
3
Current status and development trend of miRNAs in osteoporosis-related research: A bibliometric analysis.微小RNA在骨质疏松症相关研究中的现状与发展趋势:一项文献计量分析
Folia Histochem Cytobiol. 2021;59(4):203-211. doi: 10.5603/FHC.a2021.0024. Epub 2021 Dec 1.
4
Identification of a Potential MiRNA-mRNA Regulatory Network for Osteoporosis by Using Bioinformatics Methods: A Retrospective Study Based on the Gene Expression Omnibus Database.基于基因表达综合数据库的生物信息学方法鉴定骨质疏松症潜在的 miRNA-mRNA 调控网络:一项回顾性研究。
Front Endocrinol (Lausanne). 2022 May 10;13:844218. doi: 10.3389/fendo.2022.844218. eCollection 2022.
5
Role of Exosomal MicroRNAs and Their Crosstalk with Oxidative Stress in the Pathogenesis of Osteoporosis.外泌体 microRNAs 在骨质疏松症发病机制中的作用及其与氧化应激的相互作用。
Oxid Med Cell Longev. 2021 Jul 19;2021:6301433. doi: 10.1155/2021/6301433. eCollection 2021.
6
MicroRNA Alterations for Diagnosis, Prognosis, and Treatment of Osteoporosis: A Comprehensive Review and Computational Functional Survey.用于骨质疏松症诊断、预后和治疗的微小RNA改变:全面综述与计算功能研究
Front Genet. 2020 Mar 3;11:181. doi: 10.3389/fgene.2020.00181. eCollection 2020.
7
Circulating microRNA Profiles as Liquid Biopsies for the Characterization and Diagnosis of Fibromyalgia Syndrome.循环 microRNA 谱作为纤维肌痛综合征特征和诊断的液体活检。
Mol Neurobiol. 2017 Nov;54(9):7129-7136. doi: 10.1007/s12035-016-0235-2. Epub 2016 Oct 29.
8
Circulating microRNA expression signatures accurately discriminate myalgic encephalomyelitis from fibromyalgia and comorbid conditions.循环 microRNA 表达谱可准确区分肌痛性脑脊髓炎与纤维肌痛症和合并症。
Sci Rep. 2023 Feb 2;13(1):1896. doi: 10.1038/s41598-023-28955-9.
9
Altered MicroRNA Profile in Osteoporosis Caused by Impaired WNT Signaling.异常的 WNT 信号导致骨质疏松症中 microRNA 谱的改变。
J Clin Endocrinol Metab. 2018 May 1;103(5):1985-1996. doi: 10.1210/jc.2017-02585.
10
Bioinformatics analysis of gene and microRNA targets for fibromyalgia.纤维肌痛的基因和 microRNA 靶点的生物信息学分析。
Clin Exp Rheumatol. 2021 Jan-Feb;39(1):21-31. doi: 10.55563/clinexprheumatol/iitbcp. Epub 2020 Feb 14.

引用本文的文献

1
Management of Fibromyalgia: Novel Nutraceutical Therapies Beyond Traditional Pharmaceuticals.纤维肌痛的管理:超越传统药物的新型营养补充剂疗法。
Nutrients. 2025 Jan 31;17(3):530. doi: 10.3390/nu17030530.
2
miR-468-3p suppresses osteogenic differentiation of BMSCs by targeting Runx2 and inhibits bone formation.微小RNA-468-3p通过靶向Runx2抑制骨髓间充质干细胞的成骨分化并抑制骨形成。
J Orthop Surg Res. 2024 Dec 30;19(1):887. doi: 10.1186/s13018-024-05410-7.
3
Sex dimorphic response to osteocyte miR21 deletion in murine calvaria bone as determined by RNAseq analysis.

本文引用的文献

1
A case-control analysis of the associations between Fibromyalgia Syndrome and Osteoporosis.纤维肌痛综合征与骨质疏松症关联的病例对照分析。
Isr Med Assoc J. 2022 Nov;24(11):737-740.
2
Bone-Metabolism-Related Serum microRNAs to Diagnose Osteoporosis in Middle-Aged and Elderly Women.用于诊断中老年女性骨质疏松症的骨代谢相关血清微小核糖核酸
Diagnostics (Basel). 2022 Nov 19;12(11):2872. doi: 10.3390/diagnostics12112872.
3
Cholinergic receptor-Wnt pathway controls immune activation by sensing intestinal dysfunction.胆碱能受体-Wnt 通路通过感知肠道功能障碍来控制免疫激活。
通过RNA测序分析确定小鼠颅骨骨中对骨细胞miR21缺失的性别二态性反应。
JBMR Plus. 2024 Apr 18;8(6):ziae054. doi: 10.1093/jbmrpl/ziae054. eCollection 2024 Jun.
Cell Rep. 2022 Nov 1;41(5):111575. doi: 10.1016/j.celrep.2022.111575.
4
Analgesic Medication in Fibromyalgia Patients: A Cross-Sectional Study.纤维肌痛患者的镇痛药物使用:一项横断面研究。
Pain Res Manag. 2022 Sep 22;2022:1217717. doi: 10.1155/2022/1217717. eCollection 2022.
5
MicroRNA-455-3p promotes osteoblast differentiation via targeting HDAC2.miRNA-455-3p 通过靶向 HDAC2 促进成骨细胞分化。
Injury. 2022 Nov;53(11):3636-3641. doi: 10.1016/j.injury.2022.08.047. Epub 2022 Aug 21.
6
Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.Wnt信号通路和硬化蛋白在骨骼中的作用以及作为骨骼疾病的治疗靶点。
Osteoporos Int. 2023 Feb;34(2):213-238. doi: 10.1007/s00198-022-06523-7. Epub 2022 Aug 18.
7
miR-215-5p regulates osteoporosis development and osteogenic differentiation by targeting XIAP.miR-215-5p 通过靶向 XIAP 调节骨质疏松症的发生发展和成骨分化。
BMC Musculoskelet Disord. 2022 Aug 17;23(1):789. doi: 10.1186/s12891-022-05731-w.
8
MiR-100-5p inhibits osteogenic differentiation of human bone mesenchymal stromal cells by targeting TMEM135.微小RNA-100-5p通过靶向跨膜蛋白135抑制人骨髓间充质干细胞的成骨分化。
Hum Cell. 2022 Nov;35(6):1671-1683. doi: 10.1007/s13577-022-00764-8. Epub 2022 Aug 10.
9
microRNA-25-3p suppresses osteogenic differentiation of BMSCs in patients with osteoporosis by targeting ITGB3.微小RNA-25-3p通过靶向整合素β3抑制骨质疏松症患者骨髓间充质干细胞的成骨分化。
Acta Histochem. 2022 Aug;124(6):151926. doi: 10.1016/j.acthis.2022.151926. Epub 2022 Jun 28.
10
Fibromyalgia: one year in review 2022.纤维肌痛:2022 年回顾一年。
Clin Exp Rheumatol. 2022 Jun;40(6):1065-1072. doi: 10.55563/clinexprheumatol/if9gk2. Epub 2022 Jun 22.